Skip to content
Orpha Biotech
  • ABOUT US
  • OUR APPROACH
  • PIPELINE
  • RARE DISEASE COMMUNITY
  • PUBLICATIONS
  • NEWS
Menu Close
  • ABOUT US
  • OUR APPROACH
  • PIPELINE
  • RARE DISEASE COMMUNITY
  • PUBLICATIONS
  • NEWS

EUROPEAN PATENT APPLICATION GRANTED FOR INHIBITORS OF THE uPAR/FPRs RECEPTOR INTERACTION

  • Post published:January 7, 2026

Rome, 7 January 2026 – Cube Labs S.p.A. (“Cube Labs” or the “Company”) – an Italian venture builder in the healthcare technology sector listed on Euronext Growth Milan, Professional Segment…

Continue ReadingEUROPEAN PATENT APPLICATION GRANTED FOR INHIBITORS OF THE uPAR/FPRs RECEPTOR INTERACTION

Orpha Biotech Receives Seed Capital From CDP’s Southern Italy Business Fund

  • Post published:July 15, 2020

Orpha Biotech has received seed investment from CDP Venture Capital - National Innovation Fund of Italy’s "Italy Venture II - Southern Italy Business Fund." The fund aims to support outstanding…

Continue ReadingOrpha Biotech Receives Seed Capital From CDP’s Southern Italy Business Fund

ORPHA BIOTECH S.R.L.

P.Iva: 04981870753
via Mangionello, 12
73024 Maglie (Lecce) – Italy

Search

Powered by:

Copyright® by Orpha Biotech Srl | Vat N. 04981870753